FrancophonIA/ELRC3.0 huggingface dataset:
English: Pharmacotherapeutic group: Drugs used in diabetes, Dipeptidyl peptidase 4 (DPP-4) inhibitors, ATC code: A10BH01.
Croatian: Farmakoterapijska skupina: Lijekovi za liječenje šećerne bolesti, inhibitori dipeptidil-peptidaze 4 (DPP-4), ATK oznaka: A10BH01.
English: When Ristaben is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see section 4.4).
Croatian: Kada se Ristaben uzima u kombinaciji sa sulfonilurejom ili inzulinom, može se razmotriti niža doza sulfonilureje ili inzulina kako bi se smanjio rizik od hipoglikemije (vidjeti dio 4.4).
English: Sitagliptin was not carcinogenic in mice.
Croatian: Kod miševa nije bio karcinogen.
English: This medicine has no or negligible influence on the ability to drive and use machines.
Croatian: Ovaj lijek ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Paediatric No studies with Ristaben have been performed in paediatric patients.
Croatian: Pedijatrijska populacija Nisu provedena ispitivanja lijeka Ristaben u pedijatrijskih bolesnika.
English: • a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.
Croatian: • sa sulfonilurejom kada dijeta i tjelovježba uz najvišu podnošljivu dozu same sulfonilureje ne omogućuju odgovarajuću regulaciju glikemije, a metformin nije prikladan za liječenje zbog kontraindikacija ili nepodnošljivosti.
English: The decrease in body weight with the combination of sitagliptin and metformin was similar to that observed with metformin alone or placebo; there was no change from baseline for patients on sitagliptin alone.
Croatian: Smanjenje tjelesne težine u skupini koja je uzimala kombinaciju sitagliptina i metformina bilo je slično onomu opaženom u skupini koja je uzimala samo metformin ili placebo; u bolesnika koji su uzimali samo sitagliptin nije bilo promjene u odnosu na početne vrijednosti.
English: In clinical studies, approximately 13.5 % of the dose was removed over a 3- to 4-hour haemodialysis session.
Croatian: U kliničkim je ispitivanjima hemodijalizom u trajanju od 3-4 sata uklonjeno približno 13,5% doze lijeka.
English: Other potential causes for the event should be assessed, and alternative treatment for diabetes initiated.
Croatian: Treba procijeniti druge moguće uzroke te započeti liječenje dijabetesa drugim lijekovima.
English: In addition to the drug-related adverse experiences described above, adverse experiences reported regardless of causal relationship to medication and occurring in at least 5 % and more commonly in patients treated with sitagliptin included upper respiratory tract infection and nasopharyngitis.
Croatian: Kao dodatak gore opisanim nuspojavama povezanim s uzimanjem lijeka, nuspojave prijavljene bez obzira na uzročno-posljedičnu povezanost s liječenjem i koje se javljaju u barem 5% bolesnika i češće u bolesnika liječenim sa sitagliptinom uključivale su infekciju gornjeg respiratornog trakta i nazofaringitis.
English: No dose adjustment for Ristaben is necessary for patients with mild or moderate hepatic impairment (Child-Pugh score  9).
Croatian: Nije potrebna prilagodba doze lijeka Ristaben u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre (Child-Pugh rezultat ≤ 9).
English: Metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal impairment or end-stage renal disease (ESRD).
Croatian: Metabolizam može igrati značajniju ulogu u eliminaciji sitagliptina u bolesnika s teškim oštećenjem funkcije bubrega ili u završnoj fazi bubrežne bolesti.
English: In this study, the proinsulin to insulin ratio, a marker of efficiency of insulin synthesis and release, improved with sitagliptin and deteriorated with glipizide treatment.
Croatian: U ovom se ispitivanju omjer proinzulina i inzulina, pokazatelj učinkovitosti sinteze i otpuštanja inzulina, poboljšao kod liječenja sitagliptinom, a pogoršao kod liječenja glipizidom.
English: In addition, very slight to slight skeletal muscle degeneration was also observed histologically at doses resulting in systemic exposure levels of approximately 23 times the human exposure level.
Croatian: Histološki je, osim toga, opažena neznatna ili vrlo mala degeneracija skeletnih mišića pri dozama koje su dovele do sistemske izloženosti oko 23 puta veće od razine izloženosti u ljudi.
English: Concomitant administration of OAT3 inhibitors has not been evaluated in vivo.
Croatian: Nije ispitivana istodobna primjena s inhibitorima OAT3 in vivo.
English: There was no meaningful change from baseline in body weight in either group.
Croatian: Niti u jednoj skupini nije bilo značajnije promjene tjelesne težine u odnosu na početnu.
English: Some patients have experienced the following side effects after adding sitagliptin to metformin: Common (may affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting Uncommon (may affect up to 1 in 100 people): stomach ache, diarrhoea, constipation, drowsiness.
Croatian: U nekih su se bolesnika liječenih metforminom nakon dodavanja sitagliptina javile sljedeće nuspojave: Često (mogu se javiti u do 1 na 10 osoba): nizak šećer u krvi, mučnina, vjetrovi, povraćanje Manje često (mogu se javiti u do 1 na 100 osoba): bol u trbuhu, proljev, zatvor, omamljenost.
English: • a peroxisome proliferator-activated receptor gamma (PPAR) agonist (i.e. a thiazolidinedione) when use of a PPAR agonist is appropriate and when diet and exercise plus the PPAR agonist alone do not provide adequate glycaemic control.
Croatian: • s agonistom receptora za aktivator proliferacije peroksisoma-gama (engl. peroxisome proliferator-activated receptor gamma, PPAR) (tj. tiazolidindionom), kada je primjena agonista PPAR primjerena te kada dijeta i tjelovježba uz samo agonist PPAR ne omogućavaju odgovarajuću regulaciju glikemije.
English: In a 24-week placebo-controlled factorial study of initial therapy, sitagliptin 50 mg twice daily in combination with metformin (500 mg or 1,000 mg twice daily) provided significant improvements in glycaemic parameters compared with either monotherapy.
Croatian: U 24-tjednom placebom kontroliranom faktorijalnom ispitivanju početne terapije, sitagliptin u dozi od 50 mg dvaput na dan u kombinaciji s metforminom (500 mg ili 1000 mg dvaput na dan) doveo je do značajnih poboljšanja glikemijskih parametara u odnosu na monoterapiju svakim od tih lijekova.
English: The analysis of hospitalization for heart failure was adjusted for a history of heart failure at baseline.
Croatian: Analiza hospitalizacije zbog zatajenja srca prilagođena je za zatajenje srca u anamnezi na početku ispitivanja.
English: Least squares mean adjusted for metformin use at Visit 1 (yes/no), insulin use at Visit 1 (pre-mixed vs. non-pre-mixed [intermediate- or long-acting]), and baseline value.
Croatian: Srednje vrijednosti najmanjih kvadratnih pogrešaka prilagođenih s obzirom na primjenu metformina pri 1. posjeti (da/ne), primjenu inzulina pri 1. posjeti (predmiješani naspram nemiješanog [srednjedugog ili dugog djelovanja]) i vrijednost na početku liječenja.
English: Ristaben has not been studied in patients with severe hepatic impairment and care should be exercised (see section 5.2).
Croatian: Ristaben nije ispitivan u bolesnika s teškim oštećenjem funkcije jetre, te je potreban oprez (vidjeti dio 5.2).
English: Merck Sharp & Dohme Ltd. Shotton Lane, Cramlington Northumberland NE23 3JU United Kingdom
Croatian: Shotton Lane, Cramlington Northumberland NE23 3JU Ujedinjeno Kraljevstvo
English: Ristaben is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors.
Croatian: Ristaben pripada skupini oralnih antihiperglikemijskih lijekova koji se zovu inhibitori dipeptidil-peptidaze 4 (DPP-4).
English: Metabolism and nutrition disorders hypoglycaemia
Croatian: Poremećaji metabolizma i prehrane hipoglikemija često
English: By enhancing active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in a glucose-dependent manner.
Croatian: Podizanjem aktivnih inkretinskih razina, sitagliptin povećava otpuštanje inzulina i snižava razine glukagona ovisno o razini glukoze.
English: In addition, patients should be alerted to the risk of hypoglycaemia when Ristaben is used in combination with a sulphonylurea or with insulin.
Croatian: Bolesnike se također mora upozoriti na rizik od hipoglikemije kad se Ristaben uzima u kombinaciji sa sulfonilurejom ili s inzulinom.
English: Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal.
Croatian: Inkretinski hormoni, uključujući peptid-1 nalik glukagonu (engl. glucagon-like peptide-1, GLP-1) te inzulinotropni polipeptid ovisan o glukozi (engl. glucose-dependent insulinotropic polypeptide, GIP), tijekom dana se izlučuju u crijevima, a njihove razine rastu nakon obroka.
English: Since hepatotoxicity has been shown to correlate with induction of hepatic neoplasia in rats, this increased incidence of hepatic tumours in rats was likely secondary to chronic hepatic toxicity at this high dose.
Croatian: Budući da je utvrđena korelacija između hepatotoksičnosti i nastanka neoplazija u jetri štakora, pri tako visokoj dozi vjerojatno je povećana incidencija tumora jetre posljedica kroničnog toksičnog djelovanja na jetru.
English: All myocardial infarction (fatal and non-fatal)
Croatian: Svi slučajevi infarkta miokarda (sa smrtnim ishodom i bez njega)
English: Sitagliptin 100 mg once daily provided significant improvements in glycaemic parameters compared with placebo in two 24-week studies of sitagliptin as add-on therapy, one in combination with metformin and one in combination with pioglitazone.
Croatian: Sitagliptin u dozi od 100 mg jedanput na dan doveo je do značajnih poboljšanja glikemijskih parametara u odnosu na placebo u dva 24-tjedna ispitivanja sitagliptina kao dodane terapije, jednom u kombinaciji s metforminom i jednom u kombinaciji s pioglitazonom.
English: See TECOS Cardiovascular Safety Study below.
Croatian: Vidjeti odlomak "Ispitivanje kardiovaskularne sigurnosti TECOS" u nastavku.
English: Sitagliptin is also a substrate of p-glycoprotein, which may also be involved in mediating the renal elimination of sitagliptin.
Croatian: Sitagliptin je također supstrat p-glikoproteina koji bi također mogao posredovati u eliminaciji sitagliptina putem bubrega.
English: The pharmacokinetics of sitagliptin were generally similar in healthy subjects and in patients with type 2 diabetes.
Croatian: Osobitosti u bolesnika Farmakokinetika sitagliptina u načelu je slična u zdravih ispitanika i bolesnika s dijabetesom tipa 2.
English: The renal clearance of sitagliptin was not meaningfully altered.
Croatian: Bubrežni klirens sitagliptina nije bio značajno promijenjen.
English: For both GLP-1 and GIP, stimulation of insulin release is enhanced as glucose rises above normal concentrations.
Croatian: I za GLP-1 i za GIP vrijedi da stimuliraju otpuštanje inzulina čim se razina glukoze u krvi povisi iznad normalnih koncentracija.
English: Cases of inflammation of the pancreas (pancreatitis) have been reported in patients receiving Ristaben (see section 4).
Croatian: U bolesnika koji su uzimali lijek Ristaben prijavljeni su slučajevi upale gušterače (pankreatitis) (pogledajte dio 4.).
English: Co-administration of a single 100 mg oral dose of sitagliptin and a single 600 mg oral dose of ciclosporin increased the AUC and Cmax of sitagliptin by approximately 29 % and 68 %, respectively.
Croatian: Istodobnom primjenom jednokratne oralne doze sitagliptina od 100 mg i jednokratne oralne doze ciklosporina od 600 mg, AUC sitagliptina povećao se za približno 29%, a Cmax za približno 68%.
English: The frequency of adverse reactions identified from placebo-controlled clinical studies of sitagliptin monotherapy and post-marketing experience
Croatian: Učestalost nuspojava utvrđenih iz placebom kontroliranih kliničkih ispitivanja sitagliptina kao monoterapije i iskustva nakon stavljanja lijeka u promet
English: Decreased glucagon concentrations, along with higher insulin levels, lead to reduced hepatic glucose production, resulting in a decrease in blood glucose levels.
Croatian: Zbog snižene koncentracije glukagona, uz istodobno povišene razine inzulina, smanjuje se proizvodnja glukoze u jetri, što dovodi do sniženja razina glukoze u krvi.
English: Sitagliptin has not been demonstrated to be genotoxic in preclinical studies.
Croatian: Sitagliptin se u pretkliničkim istraživanjima nije pokazao genotoksičnim.
English: Caution should be exercised in patients with a history of pancreatitis.
Croatian: Potreban je oprez pri liječenju bolesnika s pankreatitisom u anamnezi.
English: Sitagliptin was modestly removed by haemodialysis (13.5 % over a 3- to 4-hour haemodialysis session starting 4 hours postdose).
Croatian: Sitagliptin se manjim dijelom uklanjao hemodijalizom (13,5% tijekom hemodijalize u trajanju 3 do 4 sata započete 4 sata nakon primjene doze).
English: For patients with severe renal impairment (GFR ≥ 15 to <30 mL/min) or with end-stage renal disease (ESRD) (GFR < 15 mL/min), including those requiring haemodialysis or peritoneal dialysis, the dose of Ristaben is 25 mg once daily.
Croatian: U bolesnika s teškim oštećenjem funkcije bubrega (GFR ≥ 15 do < 30 ml/min) ili onih u završnoj fazi bubrežne bolesti, (engl. end stage renal disease, ESRD) (GFR < 15 ml/min), uključujući i one kojima je potrebna hemodijaliza ili peritonealna dijaliza, doza lijeka Ristaben je 25 mg jedanput na dan.
English: If a hypersensitivity reaction is suspected, Ristaben should be discontinued.
Croatian: Pri sumnji na reakciju preosjetljivosti mora se prekinuti uzimanje lijeka Ristaben.
English: Analysis in the Intention-to-Treat Population
Croatian: Analiza u populaciji bolesnika predviđenoj za liječenje
English: Hypoglycaemia has been observed when sitagliptin was used in combination with insulin or a sulphonylurea.
Croatian: Hipoglikemija je primjećena kad se sitagliptin uzimao u kombinaciji s inzulinom ili sulfonilurejom.
English: A single-dose, open-label study was conducted to evaluate the pharmacokinetics of a reduced dose of sitagliptin (50 mg) in patients with varying degrees of chronic renal impairment compared to normal healthy control subjects.
Croatian: U provedenom otvorenom ispitivanju primjene jedne doze lijeka utvrđivala se farmakokinetika snižene doze sitagliptina (50 mg) u bolesnika s različitim stupnjevima kroničnog oštećenja funkcije bubrega u odnosu na zdrave kontrolne ispitanike.
English: Following oral administration of a 100-mg dose to healthy subjects, sitagliptin was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1 to 4 hours post-dose, mean plasma AUC of sitagliptin was 8.52 M•hr, Cmax was 950 nM.
Croatian: Nakon peroralne primjene doze od 100 mg u zdravih ispitanika sitagliptin se brzo apsorbira, a vršne koncentracije u plazmi (medijan tmax) nastupaju 1 do 4 sata nakon primjene doze; srednja vrijednost AUC sitagliptina u plazmi bila je 8,52 µM•h, a Cmax 950 nM.
English: However, when this medicine is used in combination with a sulphonylurea medicine or with insulin, low blood sugar (hypoglycaemia) can occur.
Croatian: Međutim, kad se ovaj lijek uzima u kombinaciji s lijekom iz skupine sulfonilureja ili inzulinom, može doći do sniženja šećera u krvi (hipoglikemije).
English: - If you have any further questions, ask your doctor, pharmacist, or nurse.
Croatian: - Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili medicinskoj sestri.
English: Over the course of the study, the overall estimated mean (SD) difference in HbA1c between the sitagliptin and placebo groups was 0.29 % (0.01), 95 % CI (-0.32, -0.27); p < 0.001.
Croatian: Tijekom ispitivanja, ukupna procijenjena srednja vrijednost (SD) razlike u vrijednosti HbA1c između skupine liječene sitagliptinom i one koja je primala placebo iznosila je 0,29% (0,01), 95% CI (-0,32; -0,27); p < 0,001.
English: Improvement of surrogate markers of beta cell function, including HOMA-β (Homeostasis Model Assessment-β), proinsulin to insulin ratio, and measures of beta cell responsiveness from the frequently-sampled meal tolerance test were observed.
Croatian: Homeostasis Model Assessment-β, HOMA-β), omjer proinzulina i inzulina te mjere odgovora beta stanica na temelju testa podnošljivosti često uzorkovanih obroka.
English: Renal and liver toxicity were observed in rodents at systemic exposure values 58 times the human exposure level, while the no-effect level was found at 19 times the human exposure level.
Croatian: Toksično djelovanje na bubrege i jetru opaženo je kod glodavaca pri 58 puta većoj sistemskoj izloženosti lijeku od razine izloženosti u ljudi, dok je razina bez učinka utvrđena pri 19 puta većoj od razina izloženosti u ljudi.
English: Ristaben has no or negligible influence on the ability to drive and use machines.
Croatian: Ristaben ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: HbA1c (%) at week 18.
Croatian: HbA1c (%) u 18. tjednu.
English: No dose adjustment is necessary for patients with mild to moderate hepatic impairment.
Croatian: Nije potrebna prilagodba doze u bolesnika s blagim do umjerenim oštećenjem funkcije jetre.
English: HbA1c (%) at week 26.
Croatian: HbA1c (%) u 26. tjednu.
English: - type 1 diabetes - diabetic ketoacidosis (a complication of diabetes with high blood sugar, rapid weight loss,
Croatian: - Dijabetičku ketoacidozu (komplikaciju šećerne bolesti s visokim šećerom u krvi, naglim gubitkom tjelesne težine, mučninom ili povraćanjem).
English: Therefore, to reduce the risk of hypoglycaemia, a lower dose of sulphonylurea or insulin may be considered (see section 4.2).
Croatian: Stoga se mogu razmotriti niže doze sulfonilureje ili inzulina kako bi se smanjio rizik od hipoglikemije (vidjeti dio 4.2).
English: If a dose of Ristaben is missed, it should be taken as soon as the patient remembers.
Croatian: Propusti li bolesnik dozu lijeka Ristaben, treba je uzeti čim se sjeti.
English: In the intention-to-treat population, among patients who were using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycaemia was 2.7 % in sitagliptin-treated patients and 2.5 % in placebo-treated patients; among patients who were not using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycaemia was 1.0 % in sitagliptin-treated patients and 0.7 % in placebo-treated patients.
Croatian: U populaciji bolesnika predviđenoj za liječenje, incidencija teške hipoglikemije među bolesnicima koji su na početku ispitivanja primjenjivali inzulin i/ili sulfonilureju iznosila je 2,7% u bolesnika liječenih sitagliptinom te 2,5% u onih koji su primali placebo; incidencija teške hipoglikemije među bolesnicima koji nisu primjenjivali inzulin i/ili sulfonilureju na početku ispitivanja iznosila je 1,0% u bolesnika liječenih sitagliptinom te 0,7% u onih koji su primali placebo.
English: Plasma AUC of sitagliptin was increased approximately 2-fold in patients with moderate renal impairment (GFR ≥ 30 to < 45 mL/min), and approximately 4-fold in patients with severe renal impairment (GFR < 30 mL/min), including in patients with ESRD on haemodialysis.
Croatian: AUC sitagliptina u plazmi bio je povišen približno 2 puta u bolesnika s umjerenim oštećenjem funkcije bubrega (GFR ≥ 30 do < 45 ml/min) i približno 4 puta u bolesnika s teškim oštećenjem funkcije bubrega (GFR < 30 ml/min), uključujući bolesnike na hemodijalizi u završnoj fazi bubrežne bolesti.
English: Incisor teeth abnormalities were observed in rats at exposure levels 67 times the clinical exposure level; the no-effect level for this finding was 58-fold based on the 14-week rat study.
Croatian: U štakora su opažene abnormalnosti na sjekutićima pri razinama izloženosti 67 puta višima od kliničke izloženosti; u 14-tjednom ispitivanju na štakorima utvrđeno je da razina bez učinka, s obzirom na ovaj nalaz, predstavlja izloženost 58 puta veća od razine kliničke izloženosti.
English: Treatment with GLP-1 or with DPP-4 inhibitors in animal models of type 2 diabetes has been demonstrated to improve beta cell responsiveness to glucose and stimulate insulin biosynthesis and release.
Croatian: U životinjskim modelima dijabetesa tipa 2 dokazano je da liječenje s GLP-1 ili inhibitorima DPP-4 poboljšava odgovor beta stanica na glukozu te stimulira biosintezu i otpuštanje inzulina.
English: Maternal toxicity was seen in rabbits at more than 29 times the human exposure levels.
Croatian: Toksičnost za majku viđena je kod ženki kunića pri razinama izloženosti 29 puta većim od razina izloženosti u ljudi.
English: When considering the use of sitagliptin in combination with another anti-diabetic medicinal product, its conditions for use in patients with renal impairment should be checked.
Croatian: Kada se razmatra primjena sitagliptina u kombinaciji s drugim lijekom protiv dijabetesa, mora se provjeriti koji su uvjeti primjene u bolesnika s oštećenjem funkcije bubrega.
English: With higher insulin levels, tissue glucose uptake is enhanced.
Croatian: S višim razinama inzulina poboljšava se unos glukoze u tkiva.
English: Treatment with sitagliptin at 100 mg once daily as monotherapy provided significant improvements in HbA1c, fasting plasma glucose (FPG), and 2-hour post-prandial glucose (2-hour PPG), compared to placebo in two studies, one of 18- and one of 24-weeks duration.
Croatian: Liječenje sitagliptinom u dozi od 100 mg jedanput na dan kao monoterapija dovelo je do značajnih poboljšanja razina HbA1c, glukoze u plazmi natašte i 2 sata nakon obroka u odnosu na placebo u dva ispitivanja, od kojih je jedno trajalo 18 tjedana, a drugo 24 tjedna.
English: In addition, GLP-1 lowers glucagon secretion from pancreatic alpha cells.
Croatian: Uz to, GLP-1 snižava lučenje glukagona iz alfa stanica gušterače.
English: Patients treated with sitagliptin exhibited a significant mean decrease from baseline in body weight compared to a significant weight gain in patients administered glipizide (-1.5 vs. +1.1 kg).
Croatian: Bolesnici liječeni sitagliptinom imali su značajno smanjenje srednje vrijednosti tjelesne težine (-1,5 kg) u odnosu na početne vrijednosti, dok je u bolesnika koji su liječeni glipizidom zabilježeno značajno povećanje srednje vrijednosti tjelesne težine (+1,1 kg).
English: Patients were instructed to titrate their insulin glargine dose based on fingerstick fasting glucose values.
Croatian: Bolesnici su dobili upute da titriraju dozu glargin inzulina sukladno vrijednostima glukoze u krvi iz jagodice prsta natašte.
English: Placebo-corrected mean change in HbA1c (%) (95 % CI)
Croatian: Srednja vrijednost promjene HbA1c (%) nakon korekcije u odnosu na placebo (95% CI)
English: How to store Ristaben
Croatian: Kako čuvati lijek Ristaben
English: The renal clearance was approximately 350 ml/min.
Croatian: Bubrežni klirens sitagliptina bio je približno 350 ml/min.
English: Incidence rate per patientyears*
Croatian: Stopa incidencije na 100 bolesnikgodina*
English: Film coating: poly(vinyl alcohol) macrogol 3350 talc (E553b) titanium dioxide (E171) red iron oxide (E172) yellow iron oxide (E172)
Croatian: Film ovojnica: poli(vinilni alkohol) makrogol 3350 talk (E553b) titanijev dioksid (E171) željezov oksid, crveni (E172) željezov oksid, žuti (E172)
English: Patients treated with sitagliptin had a modest increase in body weight compared to those given placebo.
Croatian: U bolesnika liječenih sitagliptinom došlo je do blagog povećanja tjelesne težine u odnosu na bolesnike koji su primali placebo.
English: Effects of other medicinal products on sitagliptin Clinical data described below suggest that the risk for clinically meaningful interactions by co-administered medicinal products is low.
Croatian: Klinički podaci, opisani u nastavku, ukazuju na nizak rizik od klinički značajnih interakcija pri istodobnoj primjeni s drugim lijekovima.